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Abstract
Background: Equitable access to vaccines has been suggested as a priority for low- and middle-income countries
(LMICs). However, it is unclear whether providing equitable access is enough to ensure health equity. Furthermore,
disaggregated data on health outcomes and benefits gained across population subgroups are often unavailable. This
paper develops a model to estimate the distribution of childhood disease cases and deaths across socioeconomic
groups, and the potential benefits of three vaccine programs in LMICs.
Methods: For each country and for three diseases (diarrhea, measles, pneumonia), we estimated the distributions of
cases and deaths that would occur across wealth quintiles in the absence of any immunization or treatment programs,
using both the prevalence and relative risk of a set of risk and prognostic factors. Building on these baseline estimates,
we examined what might be the impact of three vaccines (first dose of measles, pneumococcal conjugate, and
rotavirus vaccines), under five scenarios based on different sets of quintile-specific immunization coverage and
disease treatment utilization rates.
Results: Due to higher prevalence of risk factors among the poor, disproportionately more disease cases and
deaths would occur among the two lowest wealth quintiles for all three diseases when vaccines or treatment
are unavailable. Country-specific context, including how the baseline risks, immunization coverage, and treatment utilization
are currently distributed across quintiles, affects how different policies translate into changes in cases and deaths distribution.
Conclusions: Our study highlights several factors that would substantially contribute to the unequal distribution
of childhood diseases, and finds that merely ensuring equal access to vaccines will not reduce the health outcomes
gap across wealth quintiles. Such information can inform policies and planning of programs that aim to improve
equitable delivery of healthcare services.
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Background
With the ambitious goals of ending extreme poverty and
fighting against inequity in low- and middle-income
countries (LMICs) [1], international agencies, such as
the World Bank, have advocated for improving access to
essential services, such as healthcare and education, for
the lowest 40% of income earners [2]. Policymakers in
LMICs, where often vast inequities in health exist, are
interested in enhancing equity for both ethical and polit-
ical reasons [3, 4].
Vaccine programs have been recognized as one of the
most successful interventions in improving population
health worldwide. Efforts put forward by local govern-
ments and international agencies have contributed to rais-
ing childhood vaccine coverage in the last decade [5],
though high child mortality is still observed in LMICs,
with approximately 5.9 million under-five deaths in 2015
[6]. More recently, the Global Vaccine Action Plan and
Gavi, the Vaccine Alliance, both listed equitable access to
vaccination as their top priorities [7–9]. However, it is un-
clear whether ensuring equitable access to vaccines would
lead to health equity, which we define as equality of health
outcomes across population subgroups. To answer this
question, one needs to compare how disease burden is
distributed across subgroups before and after the intro-
duction of vaccines. However, such data on disease burden
by socioeconomic strata before and after vaccines are not
available empirically, making it difficult to design equitable
policies for populations. Furthermore, while vaccines pre-
vent diseases, access to treatment is needed in preventing
deaths among people who already contracted the disease,
which is often another source of inequity across popula-
tion subgroups. The objective of this work is therefore to
introduce an analytical approach to estimate the distribu-
tion of childhood disease cases and deaths and the bene-
fits of vaccines and treatments by socioeconomic group.
Methods
We examined three major childhood vaccine-preventable
diseases – measles, pneumonia, and diarrhea, selected as
they represented 23% of deaths as of 2015 (1%, 13%, and
9%, respectively) occurring among under-five children in
LMICs [6], and have well-established sets of risk and
prognostic factors. We studied the three corresponding
vaccines (and the treatment of the diseases they prevent),
namely measles vaccine (routine first dose, MCV1), rota-
virus vaccine (RV, against rotavirus diarrhea), and
pneumococcal conjugate vaccine (PCV, against pneumo-
coccal pneumonia).
The approach is based on the concept of population
attributable fraction (PAF) [10]. Using PAF, we quanti-
fied the contribution of sets of risk and prognostic
factors, defined as behaviors and characteristics of an
individual that can be used to estimate the likelihood of
contracting and dying from each disease. The proportion of
cases and deaths that could be attributed to the exposure of
selected sets of risk and prognostic factors are classified as
‘attributable’, and the remaining as ‘unattributable’ cases and
deaths. Our model takes advantage of the differences in the
prevalence of risk and prognostic factors across wealth
strata to estimate the distribution of cases and deaths. A
flow diagram outlining each step is presented in Fig. 1.
Analytical structure
Cases
For each risk factor among a total of n risk factors, we
defined wj as the relative weight assigned to risk factor j,
and RRj as the relative risk of risk factor j: w j ¼ RR jPn
k¼1RRk
.
Subsequently, the proportion of attributable cases (Aci)
occurring in wealth quintile i could be estimated as:
Aci ¼
Pn
j¼1w jPij
P5
m¼1
Pn
j¼1w jPmj
ð1Þ
where Pij is the prevalence of risk factor j in wealth
quintile i (Step 1 in Fig. 1). In other words, when
vaccines are not available, we would expect Aci% of
attributable proportion of cases to occur in quintile i.
In the presence of a vaccine program, we added
quintile-specific vaccine coverage (Vi) and vaccine
efficacy (E, assumed constant for simplicity) to estimate
the cases not averted by the program (Step 2 in Fig. 1),
using a simple static model:
Acv;i ¼
1−ViEð Þ
Pn
j¼1w jPij
P5
m¼1
Pn
j¼1w jPmj 1−VmEð Þ
ð2Þ
In other words, the distribution of attributable cases
would depend on the prevalence of the risk factors, the
relative risks of the risk factors, vaccine coverage, and
vaccine efficacy. We adopted a simple approach to
understand the impact of different combinations of
factors in a straightforward way, though we acknowledge
the limitations of a static model, including the absence
of herd immunity and dynamic transmissions [11, 12].
Deaths
Whether a death occurs would depend not only on the
prevalence and relative risk of each prognostic factor,
which impacts the underlying risk of mortality in each
quintile, but also on whether treatment is accessible and
effective. Similar to the step above, we first assigned
weights to each prognostic factor contributing to disease
mortality: ul ¼ RRlPp
k¼1RRk
, where ul is the relative weight
assigned to prognostic factor l and RRl is the relative risk
of prognostic factor l. We estimated the proportion of
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attributable deaths that would occur in each quintile i
when treatment is available as:
Adt;i ¼ 1−aiEffð Þ
Pp
l¼1ulPilP5
m¼1
Pp
l¼1ulPml 1−amEffð Þ
ð3Þ
where Pil is the prevalence of prognostic factor l in quin-
tile i, ai is the proportion of cases in quintile i for whom
treatment was sought, and Eff is the treatment effective-
ness. For simplicity, we assumed treatment effectiveness
to be constant across quintiles, but this assumption
could be relaxed if data on quintile-specific effectiveness
were available.
For the unattributable portion, we assumed that the
cases and deaths before accessing vaccines or treatment
were distributed equally across quintiles. In the presence
of vaccine or treatment programs, the distribution of un-
attributable cases/deaths would depend on the gradients
of vaccine or treatment coverage rates, using the simple
static formulation:
UAcv;i ¼ 1−ViEð ÞP5
m¼1 1−VmEð Þ
ð4Þ
UAdt;i ¼ 1−aiEffð ÞP5
m¼1 1−amEffð Þ
ð5Þ
Thus, formally, for each disease:
Ci ¼ Aci  TCa þ UAci  TCua ð6Þ
Di ¼ Adi  TDa þ UAdi  TDua ð7Þ
where Ci and Di are the proportion of all cases and deaths
in wealth quintile i, TCa and TCua are the proportion of
all cases attributable and unattributable to risk factors,
and TDa and TDua are the proportion of all deaths attrib-
utable and unattributable to prognostic factors.
A summary of all the symbols used and corresponding
parameters is summarized in Table 1.
Data sources
LMICs with Demographic and Health Surveys (DHS)
available after 2010 were selected (the full list is available
in Additional file 1: Section I). We first searched the lit-
erature for risk and prognostic factors with the highest
relative risks for diarrhea, measles, and pneumonia. For
each factor, we also checked its availability by
quintile-specific prevalence rate in the DHS [13]. Risk
factors that did not match with DHS variables, had poor
data quality, were not studied in systematic reviews, or
had poor variable definition were excluded (listed in
Table 2). We shortlisted four to five factors per disease
such as childhood malnutrition indicators, non-exclusive
breastfeeding, and vitamin A deficiency (Table 2, for
more details see Additional file 1: Section II).
We collected country-specific data on the proportion of
disease-specific cases and deaths that can be attributable
to sets of risk and prognostic factors. The average percent-
age of attributable cases (deaths) in the selected countries
were 73% (76%) for measles, 92% (94%) for pneumonia,
and 95% (97%) for diarrhea [14, 15]. In other words,
under-five cases and deaths for those diseases were largely
attributable to the selected risk and prognostic factors.
Outcomes and scenarios
Per disease, we first estimated the distribution of cases/
deaths across quintiles without immunization/treatment.
Fig. 1 Flow diagram of the analytical approach to estimate the distribution of cases/deaths of measles, diarrhea, and pneumonia under scenarios
with and without vaccines/treatment
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Second, we assessed the impact of vaccine or treatment pro-
grams on this distribution under five scenarios. For cases,
Scenario 1 (S1) assumes zero vaccine coverage, which cap-
tures today’s status in many LMICs for PCV and RV (not
MCV1); in other words, we estimate the counterfactual sce-
nario of how disease cases (starting with 100% cases) would
have been distributed across quintiles when vaccines are not
available. S2 incorporates differences in current vaccine
coverage across quintiles. We used vaccine coverage esti-
mates from Gavi for 2016 [16]. To obtain quintile-specific
MCV1 coverage, we multiplied these estimates with the
quintile-specific MCV1 coverage rates obtained from the
DHS. For PCV and RV, 6 and 14 out of the 41 countries
had not introduced PCV and RV, respectively. Among coun-
tries that did introduce the vaccines in 2016, the DHS did
not report vaccine coverage rates by quintiles. To estimate
quintile-specific coverage rates for PCV and RV for all coun-
tries, we first calculated the ratios of quintile-specific three-
and two-dose diphtheria-tetanus-pertussis vaccine coverage
rates and the national average in the DHS (since PCV and
RV match the latter’s three- and two-dose schedules, re-
spectively), and assumed that these ratios applied to PCV
and RV. We assumed that these vaccines only benefitted
children who received all the recommended doses (three for
PCV and two for RV), and not those who were partially vac-
cinated, even though partial vaccination may provide some
degree of protection. To examine the effect of redistributing
existing doses on health equity, S3 maintains the same total
number of vaccines available in each country as S2, but
distributes an equal number of doses to each quintile. In
other words, S3 measures how much equity gain a country
would see purely through redistribution without purchasing
any additional vaccines. S4 assumes that vaccine coverage
per quintile is proportional to the morbidity risk assigned to
that quintile. In other words, those with a higher risk of
getting the disease have a higher probability of receiving the
vaccine. Finally, to examine the effect of targeting risk
factors instead of vaccine coverage, S5 first reduces the
baseline morbidity risks of all quintiles to the lowest risk
level observed in the country (i.e., lowest prevalence of each
risk factor), such that all quintiles have the same number of
cases, and then applies the current quintile-specific vaccine
coverage.
For deaths, S1 examines the distribution of deaths
under the hypothetical scenario when no treatment is
available. S2 reflects the differences in the current treat-
ment utilization rates across wealth quintiles and how
these would lead to unequal distributions. We used the
percentage of those seeking care from a health provider
for different conditions from the DHS as treatment
coverage rates, namely the percentage who sought care
among those with acute respiratory infection (for pneu-
monia) and diarrhea; for measles, the average of the pro-
portions among those with acute respiratory infection
and diarrhea was used. S3 assumes equal treatment
coverage (at the national average) across all quintiles. S4
assumes that quintile-specific treatment coverage is
proportional to the underlying mortality risk, i.e., those
Table 1 List of symbols used and corresponding parameters and data sources
Parameter definition Symbol Parameter value Data source
Proportion of attributable cases and
deaths in quintile i
Aci, Adi See Additional file 1: Section V Authors’ estimation
Proportion of attributable cases and
deaths averted by vaccine/treatment in quintile i
Acv,i, Adt,i See Additional file 1: Section V Authors’ estimation
Proportion of all cases and deaths
attributable to risk and prognostic
factors
TCa, TDa See Additional file 1: Section IV [14]
Proportion of all cases and deaths
unattributable to risk and prognostic
factors
TCua, TDua See Additional file 1: Section IV [14]
Disease-specific relative risk of risk
factor j or prognostic factor l
RRj, RRl See Table 2 –
Relative weight assigned to risk
factor j or prognostic factor l
wj, ul – Authors’ estimation
Prevalence of risk factor j or
prognostic factor l in quintile i
Pij, Pil See Table 2 –
Vaccine effectiveness E MCV1: 0.85 (95% CI 0.83–0.87)
PCV: 0.06 (95% CI 0.03–0.09) for
clinically diagnosed pneumonia
RV: 0.14 (95% CI 0.00–0.31) for diarrhea
[17–19]
Healthcare treatment efficacy in
reducing mortality
Eff Measles: 0.62 (95% CI 0.19–0.82)
Pneumonia: 0.70 (95% CI 0.52–0.82)
Diarrhea: 0.93 (95% CI 0.83–0.98)
[19, 32, 33]
CI confidence interval, MCV1 measles vaccine first dose, PCV pneumococcal conjugate vaccine, RV rotavirus vaccine
Chang et al. BMC Medicine  (2018) 16:102 Page 4 of 13
Table 2 Risk and prognostic factors, and relative risks for morbidity and mortality, for measles, diarrhea, and pneumonia
Disease-vaccine pair Risk factors of morbidity
(relative risk magnitude is indicated in parentheses)
Prognostic factors of mortality
(relative risk magnitude is indicated
in parentheses)
Sources
Measles – Measles vaccine • Wasting: z-score < –3 SD (38.0, 95% CI
5.1–200.7); –2 SD < z-score < –3 SD
(8.5, 95% CI 1.3–42.9)
• Maternal education (3.2)a
• Having no other children vaccinated
at home (3.0)a
• Underweight: z-score < –3 SD (5.7, 95%
CI 1.8–12.4); –2 SD < z-score < –3 SD
(2.5, 95% CI 1.3–5.1)
• Stunting: z-score < –3 SD (2.5, 95% CI
1.1–6.6); –2 SD < z-score < –3 SD
(1.5, 95% CI 1.0–3.3)
• Vitamin A deficiency (2.4, 95% CI 1.6–3.5)
• Wasting: z-score < –3 SD (38.0, 95% CI
5.1–200.7); –2 SD < z-score < –3 SD
(8.5, 95% CI 1.3–42.9)
• Underweight: z-score < –3 SD (5.7, 95%
CI 1.8–12.4); –2 SD < z-score < –3 SD
(2.5, 95% CI 1.3–5.1)
• Stunting: z-score < –3 SD (2.5, 95% CI
1.1–6.6); –2 SD < z-score < –3 SD
(1.5, 95% CI 1.0–3.3)
• Vitamin A deficiency (2.4, 95% CI
1.6–3.5)
• More than one child (1.8)a
• Age at infection (NA)a
• Secondary (versus primary) exposure
(NA)a
• Infection with complication (NA)a
• Overcrowding (NA)a
• Intensity of exposure and patterns
of disease transmission (NA)a
[14, 27, 34, 35]
Pneumonia – Pneumococcal
conjugate vaccine
• Wasting: z-score < –3 SD (116.7, 95%
CI 25.2–179.3); –2 SD < z-score < –3 SD
(25.6, 95% CI 6.1–39.7)
• Non-exclusive breastfeeding: None (4.5,
95% CI 1.0–18.3); Partial (5.4, 95% CI 1.0–
20.9); Predominant (1.8, 95% CI 1.4–2.3)
• Underweight: z-score < –3 SD (2.1, 95%
CI 1.8–2.7); –2 SD < z-score < –3 SD
(1.3, 95% CI 1.2–1.4)
• Stunting: z-score < –3 SD (1.9); –2 SD
< z-score < –3 SD (1.2)b
• Zinc deficiency (1.8)a
• Vitamin A deficiency (1.6, 95% CI 1.2–2.0)
• Low birth weight (< 2500 g) (1.4)
• Exposed to household air pollution (1.4)a
• Crowding (more than five people per
household) (1.4)a
• Secondhand smoke (1.2)a
• Parental literacy level (NA)a
• Wasting: z-score < –3 SD (116.7, 95%
CI 25.2–179.3); –2 SD < z-score < –3 SD
(25.6, 95% CI 6.1–39.7)
• Non-exclusive breastfeeding: None
(51.4, 95% CI 2.1–325.9); Partial (2.8,
95% CI 1.3–5.2); Predominant
(1.9, 95% CI 1.0–4.1)
• Zinc deficiency (1.7)a
• Underweight: z-score < –3 SD (2.1, 95%
CI 1.8–2.7); –2 SD < z-score < –3 SD
(1.3, 95% CI 1.2–1.4)
• Stunting: z-score < –3 SD (1.9, 95% CI
1.0–3.6); –2 SD < z-score < –3 SD
(1.2, 95% CI 1.0–1.7)
• Vitamin A deficiency (1.6, 95% CI
1.2–2.0)
• Secondhand smoke (1.2)a
[14, 27, 28, 36, 37]
Diarrhea – Rotavirus vaccine • Wasting: z-score < –3 SD (105.8, 95%
CI 42.2–158.0); –2 SD < z-score < –3 SD
(23.3, 95% CI 8.9–35.9)
• Unsafe water source (11.2)a
• Unsafe sanitation (3.2, 95% CI 2.8–3.7)
• Mothers handwashing not practiced at
critical time (2.2)a
• Underweight: z-score < –3 SD (2.3, 95%
CI 2.1–2.8); –2 SD < z-score < –3 SD
(1.2, 95% CI 1.1–1.5)
• Non-exclusive breastfeeding: None
(2.2, 95% CI 1.5–3.2); Partial (1.5, 95%
CI 1.0–2.3); Predominant (1.2, 95% CI
1.0–1.7)
• Stunting: z-score < –3 SD (1.9, 95% CI
1.3–2.7); –2 SD < z-score < –3 SD
(1.2, 95% CI 1.1–1.5)
• Zinc deficiency (1.9)a
• No hand washing with soap (1.7)c
• Maternal literacy (1.7)a
• Having more than two children aged
under five years (1.7)a
• Wasting: z-score < –3 SD (105.8, 95%
CI 42.2–158.0); –2 SD < z-score < –3 SD
(23.3, 95% CI 8.9–35.9)
• Unsafe water source (11.2)a
• Non-exclusive breastfeeding: None (9.7,
95% CI 2.4–28.1); Partial (3.9, 95% CI
1.5–8.3); Predominant (2.1, 95% CI
1.0–4.6)
• Unsafe sanitation (3.2, 95% CI 2.8–3.7)
• Underweight: z-score < –3 SD (2.3, 95%
CI 2.1–2.8); –2 SD < z-score < –3 SD
(1.2, 95% CI 1.1–1.5)
• Zinc deficiency (2.0)a
• Stunting: z-score < –3 SD (1.9, 95% CI
1.3–2.7); –2 SD < z-score < –3 SD
(1.2, 95% CI 1.1–1.5)
• No handwashing with soap (1.7)c
• Vitamin A deficiency (1.5)b
[14, 27, 36, 38, 39]
aRisk factors not included in the analysis due to Demographic and Health Survey data unavailable by wealth quintile
bRisk factors not included in the analysis due to lower relative risk
cRisk factors not included in the analysis due to poor data quality and/or poor variable definition
CI confidence interval, NA not available, SD standard deviation
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with a higher risk of dying from the disease have a higher
probability of receiving treatment. Finally, S5 assumes that
the prevalence of all prognostic factors are set at the
lowest level observed in the country for all quintiles and
applies the most recent DHS-reported quintile-specific
treatment coverage rates.
For each scenario, we calculated (1) the proportion of
cases and deaths by quintile, and (2) the change in the
distribution of remaining cases and deaths. For (1), we
assumed a starting point of 100% of cases or deaths
when no vaccine or treatment programs were present
and calculated the reduction in the total burden under
each scenario. For (2), we explored the area under the
curve (AUC) of the cumulative percentage of cases
(or deaths) by quintile, and calculated the changes in
the AUC per scenario. For example, an increase in
the AUC after implementation of a vaccine program
suggests that, among the remaining cases not averted
by the program, a higher percentage of cases would
be among the poorer quintiles compared to prior
vaccine introduction. A detailed description of the
methods, including an illustration of how the distri-
butions and the AUCs were estimated, can be found
in Additional file 1: Section IV.
We calculated 95% uncertainty ranges for our esti-
mates using Monte Carlo simulations (n = 1000 draws),
while varying the relative risks of risk and prognostic
factors, vaccine efficacy, and treatment effectiveness
simultaneously using truncated normal distributions
with the inputs’ means and standard deviations.
Sensitivity analyses
Two sets of sensitivity analyses were conducted. First,
we accounted for the differences in the sizes of the
under-five population in each quintile by adjusting the
number of cases and deaths with the quintile-specific total
fertility rate (TFR). Second, instead of assuming that
unattributable cases and deaths were distributed equally
across quintiles, we used the ratios of quintile-specific
under-five mortality rates to the national average for
adjustment.
Results
Estimates for all countries are available in Additional file 1:
Section IV. To illustrate, we display our findings for each
disease for three populous country examples – Nigeria,
Pakistan, and Ethiopia.
Measles cases
Under the hypothetical scenario of no vaccines (S1),
more measles cases would occur among the lower
wealth quintiles. In Nigeria, Pakistan, and Ethiopia, the
two lowest quintiles would account for 48.8% (95%
uncertainty range 48.0–50.0), 50.3% (48.9–51.8), and
47.6% (46.5–48.6) of all cases, in comparison to 31.7%
(30.7–32.4), 30.7% (29.3–32.2), and 32.1% (31.4–32.9) in
the two highest quintiles (S1, Fig. 2). With MCV1 (S2),
in which coverage is greater among the higher quintiles,
a larger proportion of cases would be averted in these
quintiles. Compared to S1, AUC would increase by
19.0% (18.0–19.8), 14.6% (13.8–15.4), and 12.1% (11.4–
12.8), respectively, in the three countries, suggesting that
more measles cases would occur among the lowest
two quintiles than the highest two. S3 assumes equal
number of MCV1 across quintiles, and thus the same
number of cases would be averted per quintile, lead-
ing to a larger AUC than for S1 (since the lowest
quintiles would have more remaining cases because of
the unequal distribution of baseline morbidity risk ex
ante), but smaller increases in AUC than for S2
(more equal distribution of the vaccine). This effect
would be greater in countries with greater inequalities
in vaccine coverage rates, such as Nigeria (16% in the
lowest quintile versus 93% in the highest quintile)
and Pakistan (36% versus 86%). Distributing MCV1
proportionally to quintile-specific risks (S4) would
substantially reduce the unequal distribution (decrease
in AUC) for all three countries. In S5, we estimated a
larger proportion of cases being averted (compared to
S2 and S3) in Nigeria and Pakistan, suggesting that
addressing the underlying morbidity is an effective
strategy to reduce overall burden in countries with
greater unequal risk distribution.
Pneumonia cases
Without vaccines, pneumonia cases are estimated to be
concentrated among the lower quintiles (S1) (Fig. 3).
Even though the differences in PCV coverage across
quintiles would be large (for example, an average of 21%
in the lowest two quintiles versus close to 100% in the
highest two quintiles in Nigeria), the introduction of
PCV would have a limited effect on the distribution of
pneumonia cases because of its low vaccine efficacy (6%
for clinically diagnosed pneumonia [17]). Under the
current vaccine coverage scenario (S2), we estimate
small but positive increases in AUC due to the un-
equal distribution of vaccines. Even after equalizing
dosage distribution, minimal changes would occur in
both the number of cases averted and the relative
distribution of the remaining cases (S3). Distributing
PCV in proportion to baseline risks would lead to a
slightly greater number of total cases averted, but the
reductions in AUC would not be significant (S4).
Instead, equalizing baseline risks first and then applying
current coverage rates would lead to small improvements
in both the number of averted cases and AUC in all three
countries.
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Diarrhea cases
Among the three countries, only Ethiopia introduced RV
in 2016 (Fig. 4). Similar to PCV, the effect of RV on the
distribution of diarrhea cases is smaller than MCV1 due
to lower vaccine efficacy (14% for all diarrhea [18]).
Current vaccine coverage (S2) or providing equal
vaccine coverage (S3) would result in a small increase in
AUC as higher proportions of cases would be averted
among the higher wealth quintiles. Equalizing the under-
lying risks (S5), on the other hand, would both increase
the size of the total cases averted and result in more
equal case distribution (decrease in AUC).
Fig. 3 Distribution of pneumonia cases by wealth quintile and scenario in Nigeria, Pakistan, and Ethiopia. The numbers in the green boxes
represent the percentage of cases in each wealth quintile. Wealth quintiles: I = Lowest, II = Lower, III = Middle, IV = Higher, V = Highest. AUC = area
under the curve. Δ AUC: Percent change in AUC compared to Scenario 1 (S1). 95% uncertainty ranges are indicated in parentheses. (S1): no
vaccine program available; S2: current vaccine program; S3: total number of vaccines from S2 distributed equally across quintiles; S4: vaccine
coverage proportional to quintile-specific baseline morbidity risks; S5: equal baseline morbidity risk with current quintile-specific vaccine coverage
Fig. 2 Distribution of measles cases by wealth quintile and scenario in Nigeria, Pakistan, and Ethiopia. The numbers in the green boxes represent
the percentage of cases in each wealth quintile. Wealth quintiles: I = Lowest, II = Lower, III = Middle, IV = Higher, V = Highest. AUC = area under the
curve. Δ AUC: Percent change in AUC compared to Scenario 1 (S1). 95% uncertainty ranges are indicated in parentheses. (S1): no vaccine
program available; S2: current vaccine program; S3: total number of vaccines from S2 distributed equally across quintiles; S4: vaccine coverage
proportional to quintile-specific baseline morbidity risks; S5: equal baseline morbidity risk with current quintile-specific vaccine coverage
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Measles deaths
Each quintile faces different disease-specific mortality
rates due to differences in the prevalence of prognostic
factors and the probability of receiving treatment. When
treatment is not available, deaths among measles cases
would be concentrated in the lowest two quintiles (S1).
When seeking treatment under current quintile-specific
treatment coverage rates (S2), these unequal distributions
remain because the proportion of people receiving
treatment is much lower among the bottom quintiles; the
differences in the treatment coverage rates between the
highest and lowest quintiles were 28% in Nigeria, 23% in
Pakistan, and 39% in Ethiopia (Fig. 5). S3 assumes equal
treatment coverage for all quintiles, resulting in no distri-
butional change (from S1) from the unequal distribution
of the underlying mortality risks. If treatment coverage
were proportional to underlying mortality risk (S4), we
would expect to see small increases in the percentage of
deaths averted by treatment and decreases in AUC in each
country (though not significant given the large confidence
interval around treatment effectiveness for measles (0.62,
95% CI 0.19–0.82 [19])). If, instead, the unequal distribu-
tion of underlying mortality risk was flattened and current
quintile-specific treatment coverage was maintained, we
would expect a more equal distribution of deaths (larger
decreases in AUC) (S5).
Pneumonia deaths
Under S1, the lowest two wealth quintiles would have ex-
perienced close to half of deaths in Nigeria, Pakistan, and
Ethiopia (Fig. 6). Under current treatment coverage pat-
terns, 51.4% (50.2–52.6), 51.9% (50.0–53.9), and 52.3%
(49.9–54.2) of pneumonia deaths would respectively occur
among the lowest quintiles in each country (S2). When
applying equal treatment utilization across quintiles (S3),
we would expect the distribution of these deaths to re-
main the same as S1. If, instead, we increased treatment
coverage among the bottom quintiles by setting treatment
coverage proportional to baseline mortality risk, we would
expect a more equal distribution of deaths (decreases in
AUC) (S4) in most countries. This is especially visible in
Pakistan, since the baseline mortality risk is estimated to
be much higher among the lowest quintiles. Equalizing
the baseline mortality risk first and then applying current
quintile-specific treatment coverage would also lead to a
more equal distribution of deaths. Similar to measles
deaths, if we lower and equalize the underlying mortality
risk, we would expect more equal distribution of deaths
(larger decreases in AUC) (S5).
Diarrhea deaths
Under S1, 47.0% (46.2–47.7), 49.1% (47.7–50.7), and
48.6% (46.6–50.4) of deaths would occur in the lowest
Fig. 4 Distribution of diarrhea cases by wealth quintile and scenario in Ethiopia. The numbers in the green boxes represent the percentage of cases in
each wealth quintile. Wealth quintiles: I = Lowest, II = Lower, III = Middle, IV = Higher, V = Highest. AUC = area under the curve. Δ AUC: Percent change
in AUC compared to Scenario 1 (S1). 95% uncertainty ranges are indicated in parentheses. (S1): no vaccine program available; S2: current vaccine
program; S3: total number of vaccines from S2 distributed equally across quintiles; S4: vaccine coverage proportional to quintile-specific baseline
morbidity risks; S5: equal baseline morbidity risk with current quintile-specific vaccine coverage
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two quintiles in Nigeria, Pakistan, and Ethiopia, respect-
ively (Fig. 7). Current quintile-specific treatment cover-
age (S2) increases AUC in all three countries due to
higher treatment coverage rates among the higher
wealth quintiles. If treatment coverage were proportional
to underlying mortality risk, we would see improve-
ments in the distribution of deaths for all three countries
(decreases in AUC) (S4). This strategy would be more
favorable than others in countries with less equal distri-
bution of the underlying mortality risk such as Pakistan.
Fig. 6 Distribution of pneumonia deaths by wealth quintile and scenario in Nigeria, Pakistan, and Ethiopia. The numbers in the green boxes
represent the percentage of deaths in each wealth quintile. Wealth quintiles: I = Lowest, II = Lower, III = Middle, IV = Higher, V = Highest. AUC = area
under the curve. Δ AUC: Percent change in AUC compared to Scenario 1 (S1). 95% uncertainty ranges are indicated in parentheses. (S1): distribution of
deaths when no treatment is available; S2: current quintile-specific treatment coverage rates; S3: national average of treatment coverage for all
quintiles; S4: treatment coverage proportional to quintile-specific baseline mortality risks; S5: equal baseline mortality risk with current quintile-specific
treatment coverage rates
Fig. 5 Distribution of measles deaths by wealth quintile and scenario in Nigeria, Pakistan, and Ethiopia. The numbers in the green boxes represent the
percentage of deaths in each wealth quintile. Wealth quintiles: I = Lowest, II = Lower, III = Middle, IV = Higher, V = Highest. AUC = area under the curve.
Δ AUC: Percent change in AUC compared to Scenario 1 (S1). 95% uncertainty ranges are indicated in parentheses. (S1): distribution of deaths when no
treatment is available; S2: current quintile-specific treatment coverage rates; S3: national average of treatment coverage for all quintiles; S4: treatment
coverage proportional to quintile-specific baseline mortality risks; S5: equal baseline mortality risk with current quintile-specific treatment coverage rates
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Sensitivity analysis
The results of the two sets of sensitivity analyses are pre-
sented in Additional file 1: Section VI. With the TFR ad-
justment, higher TFR in lower wealth quintiles would lead
to a greater number of susceptible children and therefore
larger proportions of cases and deaths in these quintiles
under S1. Therefore, the estimated effect of vaccines and
treatments would be intensified because of the greater un-
equal distribution of underlying morbidity and mortality
risks. When we replaced the equal distribution of unattrib-
utable cases and deaths with the ratio of under-five mortal-
ity rates to the national average, we found that most of the
results were not different from the main findings, and that
the changes were more favorable (more equal distribution
of cases and deaths across quintiles).
Discussion
Equity is increasingly gaining attention on the global de-
velopment agenda [2, 4]. To understand whether certain
health interventions can lead to changes in health equity,
we developed an analytical approach to estimate the
changes in the distribution of childhood disease-related
incidence and mortality by wealth quintile with selected
interventions. In particular, we applied this approach to
examine how vaccine programs might affect health
equity under different scenarios of intervention coverage
and treatment utilization assumptions in LMICs.
Our study highlighted several factors that can substan-
tially contribute to the unequal distribution of childhood
disease. First, higher prevalence of risk factors, such as
childhood malnutrition indicators, among the poor
contribute to unequal distribution of childhood disease
incidence and mortality, before any intervention
(immunization or treatment) is even introduced. Second,
large differences were observed in vaccine coverage across
quintiles. In many countries, vaccine coverage among the
top quintiles can be three-to-four times higher than
among the bottom quintiles. Third, an unequal distribu-
tion of deaths was caused by the combination of unequal
distribution of prognostic factors (thus an unequal mortal-
ity risk) and treatment coverage rates across quintiles. Our
results suggest that the most appropriate strategy to
remedy childhood disease inequities for each country
would depend on country context, namely on how the
baseline risks and current vaccine and treatment coverage
are distributed across population subgroups.
The Global Vaccine Action Plan listed equity as a major
principle in delivering universal access to immunization
[7]; it emphasized “equitable access to immunization” as a
core component of the right to health, and suggested that
closing the coverage gap between the lowest and highest
wealth quintiles would lead to greater equity. However, as
shown in this study, merely ensuring equal access to vac-
cines will not reduce the health outcomes gap across
wealth quintiles (see Scenario 3 in Figs. 2, 3, and 4). The
Fig. 7 Distribution of diarrhea deaths by wealth quintile and scenario in Nigeria, Pakistan, and Ethiopia. The numbers in the green boxes represent the
percentage of deaths in each wealth quintile. Wealth quintiles: I = Poorest, II = Poorer, III = Middle, IV = Richer, V = Richest. AUC = area under the curve.
Δ AUC: Percent change in AUC compared to Scenario 1 (S1). 95% uncertainty ranges are indicated in parentheses. (S1): distribution of
deaths when no treatment is available; S2: current quintile-specific treatment coverage rates; S3: national average of treatment coverage
for all quintiles; S4: treatment coverage proportional to quintile-specific baseline mortality risks; S5: equal baseline mortality risk with
current quintile-specific treatment coverage rates
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poor face higher baseline risks, which are tied to social de-
terminants of health such as wealth and education, in
addition to lower treatment coverage rates. In our study,
we find that Scenario 4 (distributing vaccines proportional
to baseline risk) would often yield the most equitable dis-
tribution of disease burden, and that unequal distribution
of vaccines that benefit the lowest wealth groups more
would be required to achieve health equity.
This study makes an important contribution to the lim-
ited publications on the assessment of the distributional
burden of childhood diseases and of the distributional im-
pact of vaccines [20–22]. It builds on previous work, ex-
tends the analysis to three childhood diseases and their
corresponding vaccines, and is replicable to a large number
of countries. Our methodology could, in fact, be extended
in the future to examine the distribution of other diseases
and the distributional impact of other health interventions,
and across other population subgroups (e.g. region, sex).
One potential application of this study is to provide in-
puts to decision-makers on how to determine appropriate
equity-enhancing strategies for countries. We presented es-
timates for several policy options, including providing equal
vaccine coverage across quintiles, targeting the poor, and
addressing the underlying risks before improving vaccine
coverage. One key input required to determine strategies is
costs. We do not have data on how much more it would
cost to increase intervention coverage across different so-
cioeconomic groups, nor do we know how much effort it
would take to address the inequities in the baseline morbid-
ity and mortality risks. Thus, while we can conclude from
our study that certain scenarios would be more effective
than others, data on costs would be required to determine
which scenario would be most cost-effective and sustain-
able under countries’ budget constraints.
This study has several limitations. First, a key limitation
lies in our simplification of disease progression. We as-
sumed that whether one gets a disease solely depended on
the prevalence and relative risk of risk factors and vaccine
coverage. As described above, this paper does not involve
dynamic transmission models, and therefore does not re-
flect the potential nonlinear effects of vaccines on disease
transmissibility and herd immunity [11, 12]. We were only
able to identify contact matrices between different age
groups [23], but not between wealth quintiles. On a related
note, we searched for risk factors related to crowding,
household, or neighborhood density as an attempt to ac-
count for the size of susceptible populations. Households in
the lower wealth quintiles are more likely to have more
children, and therefore disease transmission rates in these
quintiles may be higher than the higher wealth quintiles
with fewer children. However, we were unable to find the
relative risks of related risk factors and/or the prevalence of
these risk factors by wealth quintile in DHS. Furthermore,
non-specific effects of vaccines, such as their effect on
overall mortality [24], as well as the timeliness of receiving
the vaccines [25, 26], were not taken into account. We be-
lieve that including these factors would lead to a more
skewed distribution of cases. Second, two other important
modes of delivery for measles vaccination, measles second
dose and supplementary immunization activities, were not
included in the analysis due to lack of coverage data by
quintile. Third, for some countries, the DHS did not have
complete data on the prevalence of risk and prognostic fac-
tors by wealth quintile, so we assumed they were at the
same levels as neighboring or similar countries. Fourth,
when taking the PAF approach, it is important that the def-
inition of exposure and the studied population sample
match closely with the prevalence data. For simplicity, we
selected input data sources for risk factors from highly cited
systematic reviews [14, 27, 28], and they may not perfectly
meet the definitions of the prevalence data from the DHS.
Similarly, the results depend on the selected data sources
such as inputs for vaccine efficacy and treatment effective-
ness. Since, for simplicity, we assumed they were constant
across quintiles, changing the data sources would not lead
to large changes in the results. However, we acknowledge
that there are other data sources that could be equally suit-
able for this study [29–31]. We also reflected the uncertain-
ties around these data sources by estimating uncertainty
ranges for our results. However, we did not incorporate un-
certainty around estimates of vaccine coverage, treatment
coverage, and risk factor prevalence, due to the lack of im-
mediate availability of uncertainty ranges from the original
data sources. Finally, we were not able to validate the accur-
acy of the estimates since empirical data, especially for the
null counterfactual scenario, were not available. One alter-
native for verification would be to collect disease-specific
morbidity and mortality data at the subnational or national
levels and examine the relationship between their respective
wealth and socioeconomic levels. Our work points to these
important data collection needs in the future.
Conclusions
Our findings contribute toward understanding how
diseases and the benefits of health interventions might be
distributed, specifically in relation to achieving Sustainable
Development Goal 3 in ensuring essential health services
are provided for all. Achieving equity in health outcomes
will only occur in step-by-step processes, which is why this
paper is important in illustrating the potential distributional
results of different approaches. The outputs can provide
decision-makers with information on the possible distribu-
tional impact of policies, and thereby help promote more
equitable resource allocation, even when empirical data are
unavailable. Furthermore, the pursuit of health equity re-
quires more than ensuring equal access to one intervention,
and rather a more systematic approach in addressing the
health gaps between population subgroups.
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